Published in Ugeskr Laeger on June 29, 1998
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth (2008) 1.93
European principles of haemophilia care. Haemophilia (2008) 1.84
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma (2001) 1.63
Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth (2004) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost (2012) 1.56
Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost (2003) 1.43
Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost (2009) 1.36
Mechanisms of hydroxyethyl starch-induced dilutional coagulopathy. J Thromb Haemost (2009) 1.26
A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest (1987) 1.19
Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res (2007) 1.17
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost (2006) 1.14
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost (2009) 1.13
Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia (2011) 1.11
Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost (2004) 1.10
Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost (2000) 1.07
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod (2005) 1.07
Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia (2005) 1.05
Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol (2001) 1.05
A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood (2000) 1.02
Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain (1996) 1.01
Prevalence of congenital homocystinuria in Denmark. N Engl J Med (1999) 1.01
Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol (2005) 1.01
Anal intercourse as a possible factor in heterosexual transmission of HTLV-III to spouses of hemophiliacs. N Engl J Med (1985) 1.01
Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci (1998) 0.99
Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol (2001) 0.98
Low molecular weight organic acids in the urine of the newborn. Acta Paediatr Scand (1977) 0.98
Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost (2007) 0.98
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol (2001) 0.96
Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels. Thromb Haemost (1997) 0.96
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal. Haemophilia (2006) 0.95
Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia (1988) 0.93
Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost (2007) 0.93
Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia (2010) 0.93
The Glostrup Population Studies, 1964-1992. Dan Med Bull (1992) 0.92
Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood (2000) 0.91
Tissue-specific expression in the salivary glands of transgenic mice. Nucleic Acids Res (1992) 0.91
von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). Thromb Haemost (1998) 0.90
Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest (2006) 0.90
Thrombosis in inherited factor VII deficiency. J Thromb Haemost (2003) 0.90
Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol (1999) 0.89
Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of the A-subunit. Blood (1996) 0.89
Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Thromb Haemost (2000) 0.87
Familial thrombophilia associated with homozygosity for the cystathionine beta-synthase 833T-->C mutation. Arterioscler Thromb Vasc Biol (2000) 0.87
Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania. Haemophilia (2010) 0.87
Control of gingival hemorrhage in hemophilic patients by inhibition of fibrinolysis with tranexamic acid. J Periodontal Res (1988) 0.86
Endothelial dysfunction, ambulatory pulse pressure and albuminuria are associated in Type 2 diabetic subjects. Diabet Med (2007) 0.86
Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol (2004) 0.85
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A. J Thromb Haemost (2011) 0.85
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost (2009) 0.85
Comparison of the effects of a monounsaturated fat diet and a high carbohydrate diet on cardiovascular risk factors in first degree relatives to type-2 diabetic subjects. Eur J Clin Nutr (1999) 0.84
Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis (1998) 0.84
Markers of thrombophilia in retinal vein thrombosis. Acta Ophthalmol Scand (2000) 0.83
Haemophilic patients with hepatitis C have higher viral load compared to other well-defined patient groups. J Viral Hepat (2000) 0.83
Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia (2009) 0.83
Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost (2008) 0.82
Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response. J Thromb Haemost (2005) 0.82
Fatal haemostatic complications due to thrombolytic therapy in patients falsely diagnosed as acute myocardial infarction. Eur Heart J (1992) 0.82
Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur J Pharmacol (2000) 0.82
Plasma concentrations of von Willebrand factor in patients with angina pectoris secondary to coronary atherosclerosis or cardiac syndrome X. Thromb Res (2000) 0.82
Muscle bleeds in professional athletes--diagnosis, classification, treatment and potential impact in patients with haemophilia. Haemophilia (2010) 0.81
Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia? Neuroscience (2005) 0.81
Expression of a cytomegalovirus IE-1-factor VIII cDNA hybrid gene in transgenic mice. Transgenic Res (1992) 0.80
New approaches for measuring coagulation. Haemophilia (2006) 0.80
Enzyme linked immunosorbent assay (ELISA) for the measurement of factor VIII coagulant antigen (CAg) using haemophilic antibodies. Br J Haematol (1986) 0.80
Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis (1999) 0.80
Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol (1987) 0.80
Serum ferritin and iron status in a population of 'healthy' 85-year-old individuals. Scand J Clin Lab Invest (1990) 0.79
The multimeric structure of plasma F VIII:RAg studied by electroelution and immunoperoxidase detection. Thromb Res (1986) 0.79
Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res (2010) 0.79
Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia (2006) 0.79
A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia (2011) 0.79
Haemostatic measures in type 2 diabetic patients with microalbuminuria. Diabet Med (1990) 0.79
Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatment. Eur Neuropsychopharmacol (2000) 0.79
Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology (2000) 0.79
Enzyme-linked immunosorbent assay (ELISA) for the measurement of small quantities of alpha 2-macroglobulin. Scand J Clin Lab Invest (1985) 0.79
Patient characteristics that influence efficacy of prophylaxis with rFVIII-FS three times per week: a subgroup analysis of the LIPLONG study. Haemophilia (2014) 0.79
Synthesis and secretion of alpha 2-macroglobulin by human hepatocytes in culture. Eur J Clin Invest (1988) 0.79
Total knee arthroplasty in classic hemophilia. Clin Orthop Relat Res (1990) 0.78
Insulin-gene flanking sequences, diabetes mellitus and atherosclerosis: a review. Diabetologia (1985) 0.78
Human hepatocytes exhibit receptors for alpha 2-macroglobulin and pregnancy zone protein-proteinase complexes. Eur J Clin Invest (1988) 0.78
Creatine kinase and creatine kinase subunit-B in coronary sinus blood in pacing-induced angina pectoris. Scand J Clin Lab Invest (1982) 0.78
Invasive procedures and minor surgery in factor VII deficiency. Haemophilia (2012) 0.78
Chronic antidepressant treatments decrease pro-opiomelanocortin mRNA expression in the pituitary gland: effects of acute stress and 5-HT(1A) receptor activation. J Neuroendocrinol (2001) 0.78
Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol (1997) 0.78
Extracellular levels of neuropeptide Y are markedly increased in the dorsal hippocampus of freely moving rats during kainic acid-induced seizures. Brain Res (1998) 0.78
Decrease in von Willebrand factor levels after a high-monounsaturated-fat diet in non-insulin-dependent diabetic subjects. Metabolism (1994) 0.78
Chronic treatment with citalopram induces noradrenaline receptor hypoactivity. A microdialysis study. Eur J Pharmacol (1996) 0.78
The pulmonary vasculature in a neonatal porcine model with increased pulmonary blood flow and pressure. Cardiol Young (2001) 0.77
Renal and glycemic determinants of glomerular hyperfiltration in normoalbuminuric diabetics. J Diabet Complications (1991) 0.77
Polymorphism in 5' flanking region of human insulin gene. Relationships with atherosclerosis, lipid levels, and age in three samples from Denmark. Arteriosclerosis (1990) 0.77
Dynamic APTT parameters: applications in thrombophilia. J Thromb Haemost (2012) 0.77
Pregnancy zone protein: a re-evaluation of serum levels in healthy women and in women suffering from breast cancer or trophoblastic disease. Scand J Clin Lab Invest (1990) 0.77